201 related articles for article (PubMed ID: 29874673)
1. Clinical Features and Risk Factors of Skeletal-Related Events in Genitourinary Cancer Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
Owari T; Miyake M; Nakai Y; Morizawa Y; Itami Y; Hori S; Anai S; Tanaka N; Fujimoto K
Oncology; 2018; 95(3):170-178. PubMed ID: 29874673
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study.
Owari T; Miyake M; Nakai Y; Hori S; Tomizawa M; Ichikawa K; Shimizu T; Iida K; Samma S; Iemura Y; Momose H; Omori C; Otani T; Kuwada M; Hirao S; Oyama N; Nakagawa Y; Hayashi Y; Tanaka N; Fujimoto K
Int J Urol; 2019 Jun; 26(6):630-637. PubMed ID: 30883931
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
5. Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.
Tsuda Y; Nakagawa T; Shinoda Y; Kanatani A; Kawai T; Taguchi S; Yamada Y; Sawada R; Kume H; Homma Y; Tanaka S; Kawano H
Int J Clin Oncol; 2017 Jun; 22(3):548-553. PubMed ID: 28044212
[TBL] [Abstract][Full Text] [Related]
6. A Genitourinary Cancer-specific Scoring System for the Prediction of Survival in Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma.
Owari T; Miyake M; Nakai Y; Morizawa Y; Hori S; Anai S; Tanaka N; Fujimoto K
Anticancer Res; 2018 May; 38(5):3097-3103. PubMed ID: 29715146
[TBL] [Abstract][Full Text] [Related]
7. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Saad F; Lipton A
BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
[TBL] [Abstract][Full Text] [Related]
9. Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis.
Hussain A; Aly A; Daniel Mullins C; Qian Y; Arellano J; Onukwugha E
Cancer Med; 2016 Nov; 5(11):3300-3309. PubMed ID: 27730756
[TBL] [Abstract][Full Text] [Related]
10. Skeletal-related events in urological cancer patients with bone metastasis: a multicenter study in Japan.
Yokomizo A; Koga H; Shinohara N; Miyahara T; Machida N; Tsukino H; Uozumi J; Nishiyama K; Satoh F; Sakai H; Naito S
Int J Urol; 2010 Apr; 17(4):332-6. PubMed ID: 20202004
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Lipton A; Zheng M; Seaman J
Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Miyashita H; Cruz C; Malamud S
Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
[TBL] [Abstract][Full Text] [Related]
13. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
14. Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies.
Patel SH; Panian J; Bree K; Derweesh I; Millard F; Randall J; Mckay R
Eur Urol Focus; 2020 Jan; 6(1):17-25. PubMed ID: 31255618
[TBL] [Abstract][Full Text] [Related]
15. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006.
Sathiakumar N; Delzell E; Morrisey MA; Falkson C; Yong M; Chia V; Blackburn J; Arora T; Kilgore ML
Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):177-83. PubMed ID: 21403668
[TBL] [Abstract][Full Text] [Related]
16. Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
Hong S; Youk T; Lee SJ; Kim KM; Vajdic CM
PLoS One; 2020; 15(7):e0234927. PubMed ID: 32678818
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.
Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L
Br J Cancer; 2005 Sep; 93(6):633-8. PubMed ID: 16222309
[TBL] [Abstract][Full Text] [Related]
18. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study.
Cetin K; Christiansen CF; Jacobsen JB; Nørgaard M; Sørensen HT
Lung Cancer; 2014 Nov; 86(2):247-54. PubMed ID: 25240518
[TBL] [Abstract][Full Text] [Related]
19. Molecular-targeted Therapy and Surgery May Prolong Survival of Renal Cell Carcinoma Patients with Bone Metastasis: A Multi-institutional Retrospective Study in Japan.
Kitamura H; Takahashi A; Takei F; Hotta H; Miyao N; Shindo T; Igarashi M; Tachiki H; Kunishima Y; Muranaka T; Shigyo M; Ikehata Y; Masumori N;
Anticancer Res; 2016 Oct; 36(10):5531-5536. PubMed ID: 27798926
[TBL] [Abstract][Full Text] [Related]
20. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
